Co-Authors
This is a "connection" page, showing publications co-authored by IGNACIO IVAN WISTUBA and DON LYNN GIBBONS.
Connection Strength
5.161
-
Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer. J Clin Invest. 2023 09 01; 133(17).
Score: 0.229
-
Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer. Nat Commun. 2023 04 25; 14(1):2364.
Score: 0.223
-
The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response. Genes Dev. 2022 05 01; 36(9-10):582-600.
Score: 0.208
-
Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol. 2021 01; 16(1):127-139.
Score: 0.187
-
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun. 2020 09 09; 11(1):4520.
Score: 0.186
-
Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clin Lung Cancer. 2021 05; 22(3):e415-e424.
Score: 0.183
-
Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol. 2019 09 01; 30(9):1521-1530.
Score: 0.173
-
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Sci Transl Med. 2019 03 13; 11(483).
Score: 0.168
-
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov. 2018 09; 8(9):1156-1175.
Score: 0.160
-
Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. J Thorac Oncol. 2018 06; 13(6):779-791.
Score: 0.156
-
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Ann Oncol. 2017 01 01; 28(1):83-89.
Score: 0.144
-
ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene. 2017 04 06; 36(14):1925-1938.
Score: 0.142
-
Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. Clin Cancer Res. 2016 Dec 15; 22(24):6278-6289.
Score: 0.138
-
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res. 2016 07 15; 22(14):3630-42.
Score: 0.135
-
Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One. 2009; 4(4):e5401.
Score: 0.085
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
Score: 0.062
-
The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion. Res Sq. 2024 May 15.
Score: 0.060
-
Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes. Cancer Innov. 2024 Jun; 3(3):e112.
Score: 0.060
-
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun. 2024 Apr 11; 15(1):3152.
Score: 0.060
-
Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept. Cell Rep Med. 2024 Mar 19; 5(3):101463.
Score: 0.059
-
Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis. Cancers (Basel). 2023 Oct 01; 15(19).
Score: 0.057
-
Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma. Mod Pathol. 2023 Dec; 36(12):100326.
Score: 0.057
-
EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer. Proc Natl Acad Sci U S A. 2023 07 11; 120(28):e2220276120.
Score: 0.057
-
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health. 2023 07; 5(7):e404-e420.
Score: 0.056
-
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
Score: 0.055
-
Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer. 2022 10; 172:19-28.
Score: 0.053
-
Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform. 2022 07; 6:e2200040.
Score: 0.053
-
Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clin Cancer Res. 2022 06 01; 28(11):2461-2473.
Score: 0.052
-
Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. J Exp Clin Cancer Res. 2022 May 11; 41(1):172.
Score: 0.052
-
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer. 2022 02; 10(2).
Score: 0.051
-
Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer. 2022 02; 164:69-75.
Score: 0.051
-
The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun. 2021 12 06; 12(1):7081.
Score: 0.051
-
Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun. 2021 11 17; 12(1):6655.
Score: 0.050
-
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Ann Oncol. 2022 01; 33(1):42-56.
Score: 0.050
-
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun. 2021 08 19; 12(1):5045.
Score: 0.050
-
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother. 2021 Jul; 70(7):1977-1978.
Score: 0.049
-
Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. Cancer Discov. 2021 10; 11(10):2506-2523.
Score: 0.049
-
Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. Cell Rep. 2021 04 20; 35(3):109009.
Score: 0.048
-
CD8+ T cells inhibit metastasis and CXCL4 regulates its function. Br J Cancer. 2021 07; 125(2):176-189.
Score: 0.048
-
Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel). 2021 Mar 12; 13(6).
Score: 0.048
-
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
Score: 0.048
-
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother. 2021 Jul; 70(7):1965-1976.
Score: 0.048
-
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol. 2021 04; 16(4):583-600.
Score: 0.047
-
Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol. 2020 11 04; 21(1):271.
Score: 0.047
-
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. 2020 10; 25(10):e1457-e1463.
Score: 0.046
-
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.
Score: 0.045
-
18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. 2020 Aug; 69(8):1519-1534.
Score: 0.045
-
Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. J Immunother Cancer. 2020 04; 8(1).
Score: 0.045
-
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.
Score: 0.045
-
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. J Thorac Oncol. 2020 05; 15(5):777-791.
Score: 0.045
-
Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603.
Score: 0.045
-
PI4KIII? is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma. Sci Transl Med. 2020 01 22; 12(527).
Score: 0.044
-
Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. Ann Thorac Surg. 2020 02; 109(2):358-366.
Score: 0.043
-
Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers (Basel). 2019 May 24; 11(5).
Score: 0.042
-
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov. 2019 05; 9(5):646-661.
Score: 0.042
-
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 06; 14(6):1021-1031.
Score: 0.042
-
The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest. 2018 07 02; 128(7):3198.
Score: 0.040
-
Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer. 2018 06 06; 6(1):48.
Score: 0.040
-
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol. 2018 04 01; 29(4):1072.
Score: 0.039
-
The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest. 2018 04 02; 128(4):1267-1282.
Score: 0.039
-
Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Sci Rep. 2017 10 17; 7(1):13380.
Score: 0.038
-
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097.
Score: 0.037
-
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. 2017 Apr 25; 8(17):28575-28587.
Score: 0.037
-
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol. 2017 01 01; 28(1):75-82.
Score: 0.036
-
Multiplatform-based molecular subtypes of non-small-cell lung cancer. Oncogene. 2017 03; 36(10):1384-1393.
Score: 0.036
-
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct 20; 34(30):3638-3647.
Score: 0.036
-
Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma. Mol Cancer Res. 2016 Mar; 14(3):287-95.
Score: 0.033
-
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2016 Feb 01; 22(3):609-20.
Score: 0.033
-
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014 Oct 28; 5:5241.
Score: 0.031
-
ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest. 2014 Jun; 124(6):2696-708.
Score: 0.030
-
Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS One. 2013; 8(6):e67054.
Score: 0.028
-
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov. 2013 Aug; 3(8):870-9.
Score: 0.028
-
Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression. Mol Cell Biol. 2011 Nov; 31(21):4270-85.
Score: 0.025